镭-223治疗转移性去势抵抗性前列腺癌的疼痛、健康相关生活质量与阿片类药物使用综合分析
该注册研究纳入300例接受镭-223治疗的mCRPC患者,其中105例可评估FACT-P和BPI-SF问卷。完全疼痛缓解率为31.4%,58%患者达到整合整体临床缓解,中位至疼痛进展时间和总FACT-P恶化时间分别为5.6和5.7个月。
要点
- 镭-223治疗可使31.4%的mCRPC患者达到完全疼痛缓解。
- 58%的患者获得整合整体临床缓解(疼痛、阿片使用及HRQoL综合改善)。
- 基线有无疼痛患者的中位至疼痛进展时间无显著差异。
核心结论
- 在当代经广泛预治疗的mCRPC患者中,镭-223治疗可诱导完全疼痛缓解,且多数患者从整合分析中获得临床获益。
研究设计与样本
- 注册研究纳入300例计划接受镭-223治疗的mCRPC患者,其中105例(35%)在治疗期间可评估FACT-P和BPI-SF问卷。
- 使用FACT-P和BPI-SF问卷评估HRQoL和疼痛,并记录阿片类药物使用及剂量。
主要发现
- 完全疼痛缓解率为31.4%,58%的患者达到整合整体临床缓解。
- 中位至疼痛进展时间为5.6个月,中位至总FACT-P恶化时间为5.7个月,基线有疼痛与无疼痛患者间差异无统计学意义。
关键数值与推荐
- 完全疼痛缓解定义为BPI-SF最严重疼痛项目评分为0且每日镇痛药使用未增加。
- 整合整体临床缓解定义为完全或部分疼痛缓解(BPI-SF评分改善且阿片使用减少)且HRQoL改善或无变化。
临床怎么用
- 镭-223治疗期间应综合评估疼痛、阿片类药物使用和HRQoL,以识别获得临床获益的mCRPC患者。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Radium-223 (Ra-223), an alpha-emitting radiopharmaceutical, established an improved overall survival and health-related quality of life (HRQoL) in symptomatic metastatic castration-resistant prostate cancer (mCRPC) patients. However, effects on pain were not specifically evaluated. Here we assess integrated HRQoL, pain, and opioid use in a contemporary, more extensively pretreated, symptomatic and asymptomatic mCRPC population. METHODS: mCRPC patients scheduled for Ra-223 treatment were included and analyzed for HRQoL, pain, and opioid use, using Functional Assessment of Cancer Therapy-Prostate (FACT-P) and Brief Pain Inventory-Short Form (BPI-SF) questionnaires and recording of opioid use and dosage, respectively. Primary outcome measure was the percentage of patients experiencing a complete pain response (score of 0 on the BPI-SF Worst pain item and no increase in daily use of analgesics). A complete or partial pain response (better BPI-SF score and decrease in opioid use) and a better or no change in HRQoL was evaluated as an integrated overall clinical response (IOCR). Secondary endpoints included the time to pain progression (TPP) and Total FACT-P deterioration (TTFD), defined as time from first Ra-223 treatment to clinical meaningful increase in BPI-SF Worst pain item score and Total FACT-P score, respectively. RESULTS: This registry included 300 patients, of whom 105 (35%) were evaluable for FACT-P and BPI-SF during Ra-223 treatment. Forty-five (43%) patients had pain at baseline (PAB) (BPI-SF Worst pain score 5-10 points) and 60 (57%) had no pain at baseline (no-PAB) (BPI-SF Worst pain score 0-4 points). Complete pain response was achieved in 31.4% of the patients, while 58% had an IOCR. The median TTP and TTFD were 5.6 and 5.7 months, respectively, while the difference between PAB and no-PAB patients was not significant. CONCLUSIONS: In contemporary, extensively pretreated mCRPC patients, Ra-223 treatment induced complete pain responses while integrated analysis of HRQoL, pain response, and opioid use demonstrated that the majority of patients derive clinical benefit.
引用
- Badrising SK, Louhanepessy RD, van der Noort V, et al. Integrated analysis of pain, health-related quality of life, and analgesic use in patients with metastatic castration-resistant prostate cancer treated with Radium-223. Prostate Cancer Prostatic Dis. 2021. PMID: 34446849. doi:10.1038/s41391-021-00412-6
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。